Italia markets closed

NuCana plc (N04A.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
2,4200+0,0400 (+1,68%)
Alla chiusura: 09:35AM CET
Schermo intero
Chiusura precedente2,3800
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,4200 - 2,4200
Intervallo di 52 settimane1,6400 - 5,4500
Media Volume77
Beta (5 anni mensile)0,66
Rapporto PE (ttm)N/D
EPS (ttm)-0,9020
Prossima data utili02 mar 2022 - 07 mar 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A1.138,60
  • GlobeNewswire

    NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update

    Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for the Treatment of Patients with Biliary Tract Cancer Announced Additional Encouraging Clinical Data for NUC-3373 and NUC-7738 at ESMO Multiple Near-Term Study Initiations and Data Announcements Expected EDINBURGH, United Kingdom, Nov. 18, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financia

  • GlobeNewswire

    NuCana to Present at the Jefferies 2021 London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference. Event: Jefferies 2021 London Healthcare ConferencePresentation Date: Wednesday, November 17, 2021Presentation Time: 4:20 PM GMT The presentation will be webcast live and available for replay under “Events & Presentatio

  • GlobeNewswire

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCanaEDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, inclu